BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy.
Olafur A StefanssonHolmfridur HilmarsdottirKristrun OlafsdottirLaufey TryggvadottirAsgerdur SverrisdottirOskar T JohannssonJon G JonassonJorunn E EyfjordStefan SigurdssonPublished in: JNCI cancer spectrum (2019)
BRCA1 promoter methylation is predictive of improved disease outcome in patients receiving cyclophosphamide, methotrexate, and fluorouracil drug treatment. Our results support the use of markers indicative of "BRCAness" in sporadic breast cancers to identify patients that are likely to benefit from the use of DNA-damaging agents.
Keyphrases
- dna methylation
- end stage renal disease
- high dose
- gene expression
- transcription factor
- ejection fraction
- genome wide
- newly diagnosed
- chronic kidney disease
- low dose
- peritoneal dialysis
- late onset
- circulating tumor
- locally advanced
- breast cancer risk
- radiation therapy
- combination therapy
- early onset
- adverse drug
- patient reported
- electronic health record